Entering text into the input field will update the search result below

VIVUS "excited" about return of STENDRA rights from Endo

  • Putting a positive spin on Endo International unit Auxilium Pharmaceuticals' (ENDP -1.6%) exit from its exclusive license for erectile dysfunction med STENDRA (avanafil) in the U.S. and Canada, VIVUS (VVUS +1%) CEO Seth Fischer says, "We are excited to reacquire the U.S. and Canadian commercial rights for STENDRA. We appreciate Endo's efforts to build the STENDRA brand and understand their decision to focus their resources on BELBUCA. We are in the process of evaluating ways for maximizing the value of STENDRA and expect to make an announcement by the end of [Q1 2016]."
  • The FDA cleared STENDRA in April 2012. VIVUS inked its agreement with Auxilium in October 2013.
  • BELBUCA (buprenorphine HCl buccal film) was cleared by the FDA in October 2015 for the management of pain severe enough to require around-the-clock opioid treatment. Endo secured global commercialization rights from BioDelivery Sciences (BDSI -0.2%) in January 2012.
  • Previously: Endo backs out of STENDRA license deal with VIVUS (Dec. 30)
  • Previously: Vivus, Auxilium sign Canadian marketing deal (Oct. 11, 2013)

Recommended For You

About ENDPQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ENDPQ--
Endo International plc